Effect of Licorice-Based LDD Membrane With or Without Oral Supplementation on HMGB1 Levels in GCF and Peri-Implant Marginal Bone in Type 2 Diabetic Patients: A Randomized Controlled Trial

COMPARATIVE EVALUATION OF EFFECT OF GLYCYRRHIZA GLABRA(LICORICE) BIOACTIVE LOCAL DRUG DELIVERY MEMBRANE WITH AND WITHOUT SYSTEMIC SUPPLEMENTATION ON HMGB1 LEVELS IN GINGIVAL CREVICULAR FLUID AND PERI-IMPLANT MARGINAL BONE LEVELS IN TYPE 2 DIABETICS: A RANDOMIZED CONTROLLED CLINICAL TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/111413

Enrollment

Registered

2026-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Glycyrrhiza Glabra (licorice) incorporated bioactive membrane for local drug delivery with Implant placement: 16microgram/ml Control Intervention1: Glycyrrhiza Glabra (licorice) incorpo

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with controlled Type 2 Diabetes Mellitus (HbA1c 6.1-8%)19 Patients aged between 20 years and 0 days 65 years and 0 days Patients requiring delayed implant placement Patients having adequate bone volume for implant placement Patients willing to participate and sign informed consent

Exclusion criteria

Exclusion criteria: Uncontrolled Diabetes Mellitus Patients with other systemic diseases affecting wound healing Smokers and tobacco users Pregnant and lactating females Patients on antibiotic or anti-inflammatory therapy within last 3 months Patients with active periodontal disease

Design outcomes

Primary

Measure	Time frame
HMGB1 levels in GCF using ELISA will be assessed at baseline ad 3 months Marginal Bone Levels using grid by paralleling technique by IOPA at baseline, 3 months and 6 monthsTimepoint: HMGB1 levels in GCF using ELISA will be assessed at baseline and 3 months Marginal Bone Levels using grid by paralleling technique by IOPA at baseline, 3 months and 6 months	—

Secondary

Measure	Time frame
Gingival index, Plaque index, Pocket probing depth, Fasting blood sugarTimepoint: baseline,3months,6months	—

Countries

India

Contacts

Public ContactDr Sumit Malhotra

ITS CDSR, Ghaziabad

Drprashansasharma@gmail.com7780853180

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026